Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of ...

Merck & Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29 ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Now, Merck & Co. wants in—penning a $1.9 billion biobucks deal to collaborate on new therapies for inflammatory diseases. Details remain vague, ...

Merck Foundation Together with African and Asian First Ladies Mark 'World Assisted Reproductive Technology Day' 2025 ...

Merck & Co. led the antibody-drug conjugate (ADC) shopping spree last year with its multi-billion dollar deal with Daiichi Sankyo, but now the U.S. pharma clearly wants to further fine-tune its ...